EP1490089A4 - Selektiv letale peptide für maligne und transformierte säugetierzellen - Google Patents

Selektiv letale peptide für maligne und transformierte säugetierzellen

Info

Publication number
EP1490089A4
EP1490089A4 EP03760194A EP03760194A EP1490089A4 EP 1490089 A4 EP1490089 A4 EP 1490089A4 EP 03760194 A EP03760194 A EP 03760194A EP 03760194 A EP03760194 A EP 03760194A EP 1490089 A4 EP1490089 A4 EP 1490089A4
Authority
EP
European Patent Office
Prior art keywords
malignant
mammalian cells
transformed mammalian
peptides selectively
selectively lethal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03760194A
Other languages
English (en)
French (fr)
Other versions
EP1490089A1 (de
Inventor
Matthew R Pincus
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Foundation of State University of New York
Original Assignee
Research Foundation of State University of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Foundation of State University of New York filed Critical Research Foundation of State University of New York
Publication of EP1490089A1 publication Critical patent/EP1490089A1/de
Publication of EP1490089A4 publication Critical patent/EP1490089A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
EP03760194A 2002-03-12 2003-03-12 Selektiv letale peptide für maligne und transformierte säugetierzellen Withdrawn EP1490089A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36378502P 2002-03-12 2002-03-12
US363785P 2002-03-12
PCT/US2003/007687 WO2003105880A1 (en) 2002-03-12 2003-03-12 Peptides selectively lethal to malignant and transformed mammalian cells

Publications (2)

Publication Number Publication Date
EP1490089A1 EP1490089A1 (de) 2004-12-29
EP1490089A4 true EP1490089A4 (de) 2006-08-30

Family

ID=29736031

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03760194A Withdrawn EP1490089A4 (de) 2002-03-12 2003-03-12 Selektiv letale peptide für maligne und transformierte säugetierzellen

Country Status (5)

Country Link
EP (1) EP1490089A4 (de)
JP (1) JP2005520866A (de)
AU (1) AU2003277292A1 (de)
CA (1) CA2477878C (de)
WO (1) WO2003105880A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040038902A1 (en) * 2000-04-05 2004-02-26 Pincus Matthew R. Peptides selectively lethal to malignant and transformed mammalian cells
EP1706419A2 (de) * 2004-01-13 2006-10-04 The Research Foundation of the State University of New York Aus einem domain des p53-proteins modifizierte fusionpeptide gegen malignen und/oder transformierten säugetierzellen
US7772367B2 (en) * 2004-01-30 2010-08-10 The Trustees Of Columbia University In The City Of New York C-terminal p53 palindromic peptide that induces apoptosis of cells with aberrant p53 and uses thereof
WO2008081812A1 (ja) * 2006-12-28 2008-07-10 Toagosei Co., Ltd. 抗腫瘍ペプチド及びその利用
US9539327B2 (en) 2007-11-26 2017-01-10 The Research Foundation For The State University Of New York Small molecule cancer treatments that cause necrosis in cancer cells but do not affect normal cells
US8822419B2 (en) 2008-10-03 2014-09-02 The Research Foundation Of State University Of New York Membrane resident peptide in anti-cancer peptides causes tumor cell necrosis rather than apoptosis of cancer cells
WO2011005219A1 (en) * 2009-07-07 2011-01-13 Agency For Science, Technology And Research Novel mdm2 binding peptides and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996002642A1 (en) * 1994-07-20 1996-02-01 University Of Dundee INTERRUPTION OF BINDING OF MDM2 AND p53 PROTEIN AND THERAPEUTIC APPLICATION THEREOF
WO2004081030A2 (en) * 2003-03-12 2004-09-23 The Research Foundation Of The State University Of New York Peptides selectively lethal to malignant and transformed mammalian cells

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4215102A (en) * 1979-01-05 1980-07-29 Lee Sin H Cytochemical agents and methods for the detection of steroid hormone receptors in human tissues
US5369012A (en) * 1992-03-26 1994-11-29 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Method of making a membrane having hydrophilic and hydrophobic surfaces for adhering cells or antibodies by using atomic oxygen or hydroxyl radicals

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996002642A1 (en) * 1994-07-20 1996-02-01 University Of Dundee INTERRUPTION OF BINDING OF MDM2 AND p53 PROTEIN AND THERAPEUTIC APPLICATION THEREOF
WO2004081030A2 (en) * 2003-03-12 2004-09-23 The Research Foundation Of The State University Of New York Peptides selectively lethal to malignant and transformed mammalian cells

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KANOVSKY MECHEAL ET AL: "Peptides from the amino terminal mdm-2-binding domain of p53, designed from conformational analysis, are selectively cytotoxic to transformed cells", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 98, no. 22, 23 October 2001 (2001-10-23), pages 12438 - 12443, XP002391084, ISSN: 0027-8424 *
See also references of WO03105880A1 *

Also Published As

Publication number Publication date
JP2005520866A (ja) 2005-07-14
WO2003105880A1 (en) 2003-12-24
CA2477878C (en) 2013-05-14
AU2003277292A1 (en) 2003-12-31
CA2477878A1 (en) 2003-12-24
EP1490089A1 (de) 2004-12-29

Similar Documents

Publication Publication Date Title
AU2003239159A8 (en) Placental derived stem cells and uses thereof
EP1519431A4 (de) Elektrode und elektrochemische zelle diese enthaltend
AU2003264881A1 (en) Genes and polypeptides relating to prostate cancers
EP1490089A4 (de) Selektiv letale peptide für maligne und transformierte säugetierzellen
EP1608409A4 (de) Selektiv letale peptide für maligne und transformierte säugetierzellen
AU2002351194A8 (en) Cell adhesion and extracellular matrix proteins
AU2002309989A1 (en) Directed evolution of protein in mammalian cells
AU2003295824A8 (en) Cell adhesion and extracellular matrix proteins
AU2003265431A8 (en) Cell adhesion and extracellular matrix proteins
AU2003228872A8 (en) Cell adhesion and extracellular matrix proteins
AU2003290557A1 (en) Cell cycle targets and peptides
EP1563073A4 (de) Proteinproduktionsverfahren und modifizierte zellen zur verwendung darin
AU2003225076A8 (en) Inhibition of ii expression in mammalian cells
AU2003278079A1 (en) Proteins involved in the regulation of energy homeostasis
AU2003253675A8 (en) Methods for protein analyses and protein expression in multicellular organisms and cells therefrom
GB2394477B (en) Cell culture
AU2003236851A8 (en) Proteins involved in the regulation of energy homeostasis
AU2003230992A8 (en) Peptides and methods for cell death regulation
AU2003271579A1 (en) Proteins involved in the regulation of energy homeostasis
AU2003296163A1 (en) Cell cycle-controlling protein and utilization thereof
AU2003293745A8 (en) Mammalian bt-42 proteins involved in the regulation of energy homeostasis
GB0305350D0 (en) Potential cell cycle protein and cancer
AU2003263204A8 (en) Proteins involved in the regulation of energy homeostasis
AU2003263751A8 (en) Novel proteins and their uses
AU2003294777A1 (en) Proteins involved in the regulation of energy homeostasis

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20041004

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

A4 Supplementary search report drawn up and despatched

Effective date: 20060801

17Q First examination report despatched

Effective date: 20061005

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070417